A groundbreaking development in the fight against pancreatic cancer has emerged with the introduction of an experimental drug called daraxonrasib. This new pill has shown potential in extending the lives of patients with advanced pancreatic cancer, according to recent research findings presented at the American Society for Clinical Oncology meeting in Chicago.
Promising Results
The study, which involved 500 patients with metastatic pancreatic cancer that had stopped responding to previous treatments, revealed that those taking daraxonrasib lived for a median of 13.2 months compared to 6.7 months for those receiving additional chemotherapy. The drug works by targeting a mutated protein that drives tumor growth in over 90% of pancreatic cancer cases, a target that has long eluded effective treatment.
Dr. Zev Wainberg of the University of California, Los Angeles, who co-led the study, emphasized the significance of these findings, noting that while the drug does not cure the cancer, it represents a substantial advancement over existing chemotherapy options. Patients on daraxonrasib reported fewer severe side effects, less pain, and an improved quality of life as their tumors shrank.
Future Implications
The drug’s potential to become a new standard of care for previously treated metastatic pancreatic cancer is being explored, with researchers considering its use earlier in the disease’s progression. Dr. Brian Wolpin of the Dana-Farber Cancer Institute highlighted the possibility of using the drug to shrink tumors enough to allow more patients to qualify for surgery.
Revolution Medicines, the company behind daraxonrasib, funded the study and is working with the Food and Drug Administration to expedite the drug’s review. The FDA has already initiated an “expanded access” program, allowing patients who meet specific criteria to access the drug before formal approval. The drug gained public attention when former U.S. Senator Ben Sasse shared his positive experience with it on “60 Minutes.”
Challenges and Optimism
Despite the promising results, challenges remain, such as managing side effects like severe rashes and mouth sores. However, cancer specialists not involved in the study expressed optimism, viewing this development as a potential turning point in the search for new pancreatic cancer treatments. The drug’s mechanism involves binding to multiple KRAS subtypes, a critical mutation in pancreatic cancer, using a molecular glue approach.
As researchers continue to monitor patients and explore the drug’s efficacy across different KRAS subtypes, the hope is that daraxonrasib will pave the way for more effective treatments for one of the deadliest forms of cancer.
Original reporting: WTVQ (Lexington) — read the source article.
